Concepedia

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann, Jens T. Siveke, Hana Algül, Eray Goekkurt, Gabriele Margareta Siegler, Uwe M. Martens, Dirk Waldschmidt, Uwe Pelzer, Martin Fuchs, Frank Kullmann,

˜The œLancet. Gastroenterology & hepatology · 2020 · 197 citations · 20 references

DOI

Concepts

References

20

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

, , +13

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Lola Rahib, Benjamin D. Smith, Rhonda Aizenberg et al. · Cancer Research · 2014 · 7.3K citations

, , +16

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Michel Ducreux, Caroline Caramella, Antoine Hollebecque et al. · Annals of Oncology · 2015 · 1.3K citations · Full text

, , +12

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

Pascal Hammel, F. Huguet, Jean‐Luc Van Laethem et al. · JAMA · 2016 · 1.1K citations

, , +13

Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad et al. · Journal of Clinical Oncology · 2011 · 1K citations · Full text

, , +12